JPRN-jRCT2051210097已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study of MT-8554 in Subjects with Painful Diabetic Peripheral Neuropathy
Kondou Kazuoki0 个研究点目标入组 144 人开始时间: 2021年10月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients with written consent
- •(2) Patients aged >=20 years at the time of consent
- •(3) Outpatients
- •(4) Patients with pain associated with peripheral symmetric polyneuropathy due to diabetes mellitus and pain lasting >=3 months on the first day of the run-in period. The patient should meet >=2 of the following criteria or nerve conduction studies showing abnormalities in at least one test item (Conduction velocity, amplitude, and latency) for at least two nerves by the first day of run-in period.
- •1. Subjective symptoms* thought to be due to diabetic polyneuropathy
- •2. Decreased or eliminated bilateral Achilles tendon reflexes
- •3. Bilateral decreased vibratory sense of the medial malleolus (=< 10 seconds with a C 128 tuning fork)
- •*Subjective symptoms thought to be due to diabetic neuropathy meet the following 3 criteria.
- •- Bilateral
- •- Toe and plantar symptoms (Numbness, pain or dysesthesia)
- •- Does not cause upper extremity symptoms alone
- •(5) Patients whose NRS during the run-in period is assessed for >=4 days of the 7 days immediately before the first day of the treatment period and whose baseline 24-hour mean NRS score is >=4 and =<8.
- •(6) Patients whose rate of change in the 24-hour mean NRS score during the 7 days immediately before the first day of the treatment period is <30%.
- •(7) Patients whose treatment for diabetes mellitus is consistent >=8 weeks before the run-in period, who can consistently maintain the treatment throughout the study period, and in whom the investigator (or sub-investigator) can determine that glycemic control is constant.
排除标准
- •(1) Patients with pain, disease, or skin condition that, in the opinion of the investigator (or sub-investigator), would influence the evaluation of painful diabetic peripheral neuropathy.
- •For example, if other pain is in the same location as painful diabetic peripheral neuropathy, or if the pain intensity of the other pain is greater than that of painful diabetic peripheral neuropathy, which in the opinion of the investigator (or sub-investigator) would impact the assessment of painful diabetic peripheral neuropathy.
- •(2) Patients who have had amputation of upper and lower limbs other than toes due to gangrene caused by impaired blood circulation.
- •(3) Patients who do not meet the criteria of prohibited concomitant drugs or restricted concomitant drugs.
- •(4) Patients with hypersensitivity to acetaminophen or a history of hypersensitivity to acetaminophen.
- •(5) Patients with New York Heart Association functional class III or IV symptoms of heart failure.
- •(6) History of myocardial infarction, congestive heart failure, unstable angina, or cerebrovascular disorder (excluding lacunar infarction) within 6 months prior to informed consent.
- •(7) Patients with major psychiatric disorder such as depression or anxiety disorder.
- •(8) Patients with drug abuse or a history of drug abuse.
- •(9) Patients with current or previous infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). However, patients with previous infection with hepatitis B virus who are HBsAg-negative are eligible.
- •(10) Patients with HbA1c > 10.5%.
- •(11) Patients with poorly controlled hypertension (>= 180 mmHg systolic and/or >= 110 mmHg diastolic).
- •(12) Patients with eGFR < 30 mL/min/1.73 m^2.
- •(13) Patients with AST or ALT > 2.5 * ULN.
- •(14) Patients who answered Yes to any item of Columbia Suicide Severity Rating Scale within the past 12 months.
- •(15) Patients who have a concomitant malignancy or a history of malignancy. However, patients who have a history of malignancy but have not experienced recurrence for at least 5 years before informed consent (patients who have not experienced recurrence for at least 5 years after the last administration if they were receiving anticancer drugs) will be excluded.
- •(16) Male or female patients of childbearing potential who do not agree to use contraception from the date of informed consent until 3 months after the completion (discontinuation) of investigational product.
- •(17) Female patients who are pregnant, breastfeeding or possibly pregnant.
- •(18) Patients who participated in another clinical study and received investigational product within 12 weeks before informed consent.
- •(19) Prior exposure to MT-8554.
- •(20) Other patients who, in the opinion of the investigator (or sub-investigator), are ineligible for this study.
研究者
相似试验
进行中（未招募）
1 期
A research study to determine the safety of IMB-1018972 and how it helps your heart use energy more efficiently to improve anginaStable coronary artery disease (CAD)/chronic coronary syndromeEUCTR2020-004455-32-FIImbria Pharmaceuticals, Inc.65
进行中（未招募）
1 期
A research study to determine the safety of IMB-1018972 and how it helps your heart use energy more efficiently to improve anginaStable coronary artery disease (CAD) /Chronic coronary syndromeEUCTR2020-004455-32-SEImbria Pharmaceuticals, Inc.65
进行中（未招募）
1 期
A research study to determine the safety of IMB-1018972 and how it helps your heart use energy more efficiently to improve anginaCoronary artery disease (CAD)MedDRA version: 20.0Level: LLTClassification code 10028601Term: Myocardial ischemiaSystem Organ Class: 100000004849EUCTR2020-004455-32-DKImbria Pharmaceuticals, Inc.65
进行中（未招募）
1 期
A study to investigate the mechanism of action and safety of Epeleuton capsules in the treatment of patients with type 2 diabetes and diabetic complicationsType 2 diabetes and diabetic complicationsMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: HLGTClassification code 10012653Term: Diabetic complicationsSystem Organ Class: 10014698 - Endocrine disordersEUCTR2020-002911-23-DEAfimmune25
进行中（未招募）
2 期
Safety and effects of oral ARV-1801 given in combination with intravenous ceftazidime or meropenem for treatment of melioidosis (a bacterial infection) in hospitalized patientsTreatment of melioidosis in hospitalized patientsInfections and InfestationsISRCTN14019371Arrevus, Inc.100